Inactive Instrument

Press Releases Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Press Releases

Unlock all the news: Be the first to know and act before the market!

Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	Apr. 24	AQ
Acquisition of Freeline by Syncona Becomes Effective	Feb. 20	AQ
Freeline Shareholders Approve Acquisition by Syncona	Feb. 12	AQ
Hemophilia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics	Dec. 08	AQ
Freeline Therapeutics : Reports Second Quarter 2023 Financial Results and Business Highlights - Form 6-K	Dec. 01	PU
FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN	Nov. 28	BU
FRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to Shareholders	Nov. 22	BU
Syncona to Acquire Freeline Therapeutics	Nov. 22	AQ
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress	23-10-25	AQ
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress	23-10-16	AQ
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease	23-10-04	AQ
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights	23-08-15	AQ
Freeline Therapeutics : Corporate Presentation	23-08-14	PU
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call	23-08-08	AQ
Freeline Therapeutics : Corporate Presentation – July	23-08-02	PU
Freeline to Participate in Upcoming Investor Conferences	23-07-31	AQ
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease	23-07-25	AQ
Freeline Therapeutics : Voting Results of Annual General Meeting - Form 6-K	23-06-30	PU
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease	23-06-26	AQ
Freeline to Present at 2023 Jefferies Healthcare Conference	23-06-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Press Releases

Filters